BALTIMORE, December 11, 2014 - Insilico Medicine along with
scientists from Vision Genomics and Howard University shed light on AMD
disease, introducing the opportunity for eventual diagnostic and
treatment options.
The scientific collaboration between Vision Genomics, Inc., Howard
University, and Insilico Medicine, Inc., has revealed encouraging
insight on the AMD disease using an interactome analysis approach.
Resources such as publicly available gene expression data, Insilico
Medicine's original algorithm OncoFinderTM, and AMD MedicineTM from
Vision Genomics allowed discovery of signaling pathways activated during
AMD disease.
"We are thrilled to collaborate with Alex Zhavoronkov and Evgeny
Makarev, and their team at InSilico Medicine. Big Data analysis is part
of the future of medicine, and with our technique of signaling pathway
activation analysis, we will decipher the genetic network alterations
that lead to age-related macular degeneration (AMD), and eventually
human aging itself", said Antonei Benjamin Csoka, PhD, CEO of Vision
Genomics, LLC, and Assistant Professor at Howard University.
The research publication titled "Pathway activation profiling
reveals new insights into Age-related Macular Degeneration and provides
avenues for therapeutic interventions" was accepted by one of aging
research's top-rated journals "Aging", detailing these findings
and methodology. This study not only validates the efficacy of
interactome analysis within aging, but also allows the investigation of
cellular populations within AMD models.
"We are happy to collaborate with Antonei Benjamin Csoka's teams at
both Vision Genomics and Howard University on this exciting project.
Coupling Big Data with advanced signaling pathway activation analysis
may help find new therapeutic approaches for age-related macular
degeneration (AMD), a disease that holds many keys to understanding
human aging", said Evgeny Makarev, PhD, Director of Aging Research at
Insilico Medicine.
On December 9th Insilico Medicine, Inc announced the appointment of
2013 Nobel Laureate in Chemistry, Michael Levitt, to its Scientific
Advisory Board. Dr. Levitt's background in computational modeling
focused on understanding protein folding processes and molecular
interactions, may turn to be extremely valuable for compound discovery
related to AMD and other age-related diseases. The concept utilized by
Insilico Medicine involves identifying the difference between several
signaling states on a tissue-specific level, be it health and disease,
or young and old, and evaluating a large number of drugs and drug
combinations that can modulate the difference using advanced parametric
and machine-learned algorithms. "To create more value from our
predictions we will need to identify compounds that are even more
effective than top-scoring drugs and that would require multi-scale
modeling of macromolecules, the field pioneered by Dr. Michael Levitt ",
said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc. Insilico
Medicine continues to be represented from top institutions, including
Stanford University, Johns Hopkins University, and New York University.
With this broad range of expertise, Insilico and its collaborators will
pursue AMD disease further and utilize the newly discovered activated
pathways as a foundation
No comments:
Post a Comment